ArticleKidney international reports2026
Renal Outcomes With Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors in CKD.
Article in Kidney international reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Potassium-Competitive Acid Blockers as a New Frontier in Acid-Related Disorders and the Role of South Korean Pharmacological Innovation.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Potassium-competitive acid blockers (P-CABs) have emerged as a promising alternative to proton pump inhibitors (PPIs) because of their rapid and sustained acid suppression. However, their renal safety in patients with chronic kidney disease (CKD) has not been thoroughly evaluated. Given concerns about PPI-associated renal risks, we conducted a target trial-emulated cohort study to compare renal safety of P-CABs versus PPIs. Methods: Using Korean National Health Insurance data, we identified patients with CKD newly initiating P-CABs or PPIs for gastroesophageal reflux disease (GERD) between 2019 and 2022. Patients with previous renal replacement therapy (RRT) were excluded. The primary outcome was the first initiation of RRT. Propensity score (PS) matching (1:4) was applied, and hazard ratios (HRs) were estimated using Cox proportional hazards models. An intention-to-treat (ITT) analysis was also performed. Results: A total of 34,077 patients were included, and 4107 P-CAB and 16,428 PPI users remained after matching. Over 60% in both groups were aged ≥ 65 years, and males were slightly more prevalent. P-CAB use was significantly associated with a lower risk of composite RRT initiation than PPI use (HR: 0.63, 95% confidence interval [CI]: 0.45-0.88). Although HRs for individual RRT events favored P-CABs, statistical significance was not reached. The ITT analysis showed consistent results (HR: 0.90, 95% CI: 0.82-0.99). Conclusion: In this study, P-CABs were associated with a reduced risk of renal function deterioration compared with PPIs in patients with CKD with GERD. These findings suggest the potential clinical utility of P-CABs as a safer treatment option in this high-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.